Jacobs & Co. CA Has $13.03 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Jacobs & Co. CA reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,254 shares of the medical research company’s stock after selling 739 shares during the quarter. Amgen makes up approximately 1.5% of Jacobs & Co. CA’s holdings, making the stock its 21st largest holding. Jacobs & Co. CA’s holdings in Amgen were worth $13,034,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of AMGN. Briaud Financial Planning Inc acquired a new position in Amgen during the 3rd quarter worth $26,000. OFI Invest Asset Management bought a new stake in shares of Amgen during the 3rd quarter valued at $26,000. Providence Capital Advisors LLC bought a new stake in shares of Amgen during the 3rd quarter valued at $30,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Amgen in the 1st quarter valued at $28,000. Finally, Carmel Capital Partners LLC increased its position in shares of Amgen by 296.6% in the 3rd quarter. Carmel Capital Partners LLC now owns 115 shares of the medical research company’s stock valued at $31,000 after buying an additional 86 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 1.6 %

AMGN opened at $286.30 on Thursday. The company has a fifty day moving average price of $290.44 and a 200-day moving average price of $280.66. The firm has a market capitalization of $153.43 billion, a P/E ratio of 22.92, a price-to-earnings-growth ratio of 2.63 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s revenue was up 19.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.09 EPS. Equities research analysts expect that Amgen Inc. will post 19.48 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.14%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 72.06%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on AMGN shares. Royal Bank of Canada increased their price objective on shares of Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Morgan Stanley cut their target price on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. Oppenheimer reiterated an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research note on Thursday, February 1st. UBS Group decreased their price objective on Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a report on Monday, January 29th. Finally, The Goldman Sachs Group increased their price objective on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $295.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.